Cannabinoid functions in the amygdala contribute to conditioned fear memory in streptozotocin-induced diabetic mice: Interaction with glutamatergic functions

Experimental Neurology

Volumn 269, Issue , 2015, Pages 233-241

  Ikeda, Hiroko ^a   Ikegami, Megumi ^a   Kai, Misa ^a   Kamei, Junzo ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Amygdala; Cannabinoid; Diabetes; Fear memory; Glutamatergic neurons; Mice

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMPA RECEPTOR; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DIACYLGLYCEROL LIPASE ALPHA; GLUTAMIC ACID; GLUTAMINE; LIPOPROTEIN LIPASE; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR AFFECTING AGENT; STREPTOZOCIN;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ARTICLE; BRAIN FUNCTION; CONTROLLED STUDY; ENZYME ACTIVITY; FEAR MEMORY; FREEZING; GLUTAMATERGIC SYNAPSE; HIPPOCAMPUS; MALE; MEMORY; MOLECULAR INTERACTION; MOUSE; NEUROMODULATION; NEUROPHYSIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; UPREGULATION; ANIMAL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; FEAR; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

AMYGDALA; ANIMALS; CANNABINOIDS; DIABETES MELLITUS, EXPERIMENTAL; EXCITATORY AMINO ACID AGENTS; FEAR; MALE; MEMORY; MICE; STREPTOZOCIN;

EID: 84929657064     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2015.04.012     Document Type: Article

References (38)

1. Alijanpour S., Rezayof A. Involvement of dorsal hippocampal and medial septal nicotinic receptors in cross state-dependent memory between WIN55,212-2 and nicotine or ethanol in mice. Neuroscience 2013, 245:61-73.
2. Anderson R.J., Freedland K.E., Clouse R.E., Lustman P.J. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001, 24:1069-1078.
3. Champaneri S., Wand G.S., Malhotra S.S., Casagrande S.S., Golden S.H. Biological basis of depression in adults with diabetes. Curr. Diab. Rep. 2010, 10:396-405.
4. Clapper J.R., Moreno-Sanz G., Russo R., Guijarro A., Vacondio F., Duranti A., Tontini A., Sanchini S., Sciolino N.R., Spradley J.M., Hohmann A.G., Calignano A., Mor M., Tarzia G., Piomelli D. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat. Neurosci. 2010, 13:1265-1270.
5. Degroot A., Köfalvi A., Wade M.R., Davis R.J., Rodrigues R.J., Rebola N., Cunha R.A., Nomikos G.G. CB1 receptor antagonism increases hippocampal acetylcholine release: site and mechanism of action. Mol. Pharmacol. 2006, 70:1236-1245.
6. Dove Pettit D.A., Harrison M.P., Olson J.M., Spencer R.F., Cabral G.A. Immunohistochemical localization of the neural cannabinoid receptor in rat brain. J. Neurosci. Res. 1998, 51:391-402.
7. García-Gutièrrez M.S., García-Bueno B., Zoppi S., Leza J.C., Manzanares J. Chronic blockade of cannabinoid CB2 receptors induces anxiolytic-like actions associated with alterations in GABAA receptors. Brit. J. Pharmacol. 2012, 165:951-964.
8. Gavard J.A., Lustman P.J., Clouse R.E. Prevalence of depression in adults with diabetes: an epidemiological evaluation. Diabetes Care 1993, 16:1167-1178.
9. Hermanson D.J., Hartlet N.D., Gamble-George J., Brown N., Shonesy B.C., Kingsley P.J., Colbran R.J., Reese J., Marnett L.J., Patel S. Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation. Nat. Neurosci. 2013, 16:1291-1298.
10. Ikeda H., Ikegami M., Kai M., Ohsawa M., Kamei J. Activation of spinal cannabinoid CB2 receptors inhibits neuropathic pain in streptozotocin-induced diabetic mice. Neuroscience 2013, 250:446-454.
11. Ikeda H., Saigusa T., Kamei J., Koshikawa N., Cools A.R. Spiraling dopaminergic circuitry from the ventral striatum to dorsal striatum is an effective feed-forward loop. Neuroscience 2013, 241:126-134.
12. Kamei J., Ohsawa M., Tsuji M., Takeda H., Matsumiya T. Modification of the effects of benzodiazepines on the expiratory behaviors of mice on a hole-board by diabetes. Jpn. J. Pharmacol. 2001, 86:47-54.
13. Kamei J., Miyata S., Morita K., Saitoh A., Takeda H. Effects of selective serotonin reuptake inhibitors on immobility time in the tail suspension test in streptozotocin-induced diabetic mice. Pharmacol. Biochem. Behav. 2003, 75:247-254.
14. Kano M., Ohno-Shosaku T., Hashimotodani Y., Uchigashima M., Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol. Rev. 2009, 89:309-380.
15. Katona I., Freund T.F. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat. Med. 2008, 14:923-930.
16. Katona I., Sperlágh B., Sík A., Käfalvi A., Vizi E.S., Mackie K. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J. Neurosci. 1999, 19:4544-4558.
17. Katona I., Rancz E.A., Acsády L., Ledent C., Mackie K., Hájos N., Freund T.F. Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J. Neurosci. 2001, 21:9506-9518.
18. Lazary J., Juhasz G., Hunyady L., Bagdy G. Personalized medicine can pave the way for the safe use of CB1 receptor antagonists. Trends Pharmacol. Sci. 2011, 32:270-280.
19. Lustman P.J., Anderson R.J., Freedland K.E., de Groot M., Carney R.M., Clouse R.E. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000, 23:934-942.
20. Mahan A.L., Ressler K.J. Fear conditioning, synaptic plasticity and the amygdala: implications for posttraumatic stress disorder. Trends Neurosci. 2012, 35:24-35.
21. Maren S., Phan K.L., Liberzon I. The contextual brain: implications for fear conditioning, extinction and psychopathology. Nat. Rev. Neurosci. 2013, 14:417-428.
22. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., Hermann H., Tang J., Hofmann C., Zieglgänsberger W., Di Marzo V., Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Naure 2002, 418:530-534.
23. McLaughlin R.J., Gobbi G. Cannabinoids and emotionality: a neuroanatomical perspective. Neuroscience 2012, 204:134-144.
24. Miyata S., Hirano S., Kamei J. Diabetes attenuates the antidepressant-like effect mediated by the activation of 5-HT1A receptor in the mouse tail suspension test. Neuropsychopharmacology 2004, 29:461-469.
25. Miyata S., Yamada N., Hirano S., Tanaka S., Kamei J. Diabetes attenuates psychological stress-elicited 5-HT secretion in the prefrontal cortex but not in the amygdala of mice. Brain Res. 2007, 1147:233-239.
26. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
27. Murray R.M., Morrison P.D., Henquet C., Di Forti M. Cannabis, the mind and society: the hash realities. Nat. Rev. Neurosci. 2007, 8:885-895.
28. Ohno-Shosaku T., Maejima T., Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 2001, 29:729-738.
29. Pamplona F.A., Takahashi R.N. WIN 55212-2 impairs contextual fear conditioning through the activation of CB1 cannabinoid receptors. Neurosci. Lett. 2006, 397:88-92.
30. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, New York. 2nd ed.
31. Ramikie T.S., Patel S. Endocannabinoid signalling in the amygdala: anatomy, synaptic signaling, behavior, and adaptations to stress. Neuroscience 2012, 204:38-52.
32. Rey A.A., Purrio M., Viveros M.-P., Lutz B. Biphasic effects of cannabinoids in anxiety responses: CB1 and GABAB receptors in the balance of GABAergic and glutamatergic neurotransmission. Neuropsychopharmacology 2012, 37:2624-2634.
33. Rubino T., Guidali C., Vigano D., Realini N., Valenti M., Massi P., Parolaro D. CB1 receptor stimulation in specific brain areas differentially modulate anxiety-related behaviour. Neuropharmacology 2008, 54:151-160.
34. Ruehle S., Rey A.A., Remmers F., Lutz B. The endocannabinoid system in anxiety, fear memory and habituation. J. Psychopharmacol. 2012, 26:23-39.
35. Sugiura T., Kishimoto S., Oka S., Gokoh M. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, and endogenous cannabinoid receptor ligand. Prog. Lipid Res. 2006, 45:405-446.
36. Tan H., Lauzon N.M., Bishop S.F., Chi N., Bechard M., Laviolette S.R. Cannabinoid transmission in the basolateral amygdala modulate fear memory formation via functional input to the prelimbic cortex. J. Neurosci. 2011, 31:5300-5312.
37. Tanimura A., Yamazaki M., Hashimotodani Y., Uchigashima M., Kawata S., Abe M., Kita Y., Hashimoto K., Shimizu T., Watanabe M., Sakimura K., Kano M. The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase α mediates retrograde suppression of synaptic transmission. Neuron 2010, 65:320-327.
38. Willson R.I., Nicoll R.A. Endogenous cannabinoids mediate regrograde signalling at hippocampal synapses. Nature 2001, 410:588-592.